GET DAILY SIGNALSCardio Diagnostics Holdings (CDIO) Slides -16.8% Over 30 Days: Key Drivers and Outlook
Key Takeaways
- Cardio Diagnostics Holdings (CDIO) fell about 16.8% over the past 30 days, sliding from a close of $1.97 on October 7, 2026, to $1.64 on November 6, 2026.
- The decline was gradual rather than driven by a single headline event, unfolding across a stretch of light and uneven trading volume typical of a micro-cap stock.
- Over the trailing three months, shares are roughly flat—down about 3%—reflecting elevated volatility after a sharp mid-August spike that quickly faded.
- Cardio Diagnostics is a Chicago-based molecular diagnostics company with a market capitalization near $5 million, modest revenue, and ongoing net losses as it commercializes its cardiovascular tests.
- Investors are watching the rollout of its Epi+Gen CHD and PrecisionCHD blood tests, its newly launched in-house CLIA-certified laboratory, and payer coverage agreements.
- The company is expected to report third-quarter financial results in November 2026, a key event for near-term sentiment.
Cardio Diagnostics Holdings (CDIO): Business Snapshot
Cardio Diagnostics Holdings, Inc. is a molecular diagnostics company focused on the detection and risk assessment of cardiovascular disease. Founded in 2017 and headquartered in Chicago, Illinois, the company develops epigenetics-based and AI-driven blood tests that assess risk for coronary heart disease events, including heart attacks. Its flagship products are Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test, and PrecisionCHD, an integrated epigenetic-genetic test for detecting coronary heart disease.
The company's portfolio also includes HeartRisk, a SaaS cardiovascular risk intelligence platform, and CardioInnovate360, a research-use-only solution supporting biopharmaceutical discovery and validation. Cardio Diagnostics serves telemedicine providers, concierge practices, longevity clinics, risk-bearing provider organizations, and employers. Investors follow the stock for its potential to modernize cardiovascular risk screening, though the company remains an early-stage, thinly capitalized player competing against larger, better-funded diagnostics and medical-technology firms. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
CDIO Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CDIO moved from a closing price of $1.97 on October 7, 2026, to $1.64 on November 6, 2026—a decline of approximately 16.8%. The move lower was not a single-session shock but a steady drift punctuated by brief bounces, with daily closes progressively stepping down through the second half of October and into early November.
Zooming out to the trailing three months paints a more muted picture. From a close of $1.69 in early August 2026 to $1.64 in early November, the stock is down only about 3%. That relatively flat quarterly result masks significant intra-quarter volatility: shares spiked to intraday highs above $2.20 in mid-August on a surge in volume before retracing, and then consolidated in a $1.85–$2.15 range through September before the recent leg lower. The net effect is a high-volatility, lower-liquidity name that has given back its earlier gains. From what I see, this pattern aligns with typical micro-cap behavior.
What Drove CDIO Stock Price in the Last 30 Days
The 30-day decline in CDIO does not trace to a single, widely reported catalyst. Instead, the move reflects the mechanics of a micro-cap stock with a market capitalization near $5 million and average daily volume in the tens of thousands of shares. With limited institutional sponsorship and thin order books, relatively small amounts of selling pressure can translate into outsized percentage moves.
Context matters here. The stock had posted a sharp rally in mid-August and held elevated levels into late September, leaving room for profit-taking once momentum stalled. As broader risk appetite cooled and the stock drifted below short-term support levels in the $1.80–$1.90 area, the pullback fed on itself in the absence of fresh, positive company-specific news. Ongoing concerns about the pace of commercialization, minimal reported revenue, and continuing cash burn likely also weighed on sentiment as investors awaited the next quarterly update.
What Drove CDIO Stock Performance Over the Last Quarter
The broader three-month narrative is one of a short-lived enthusiasm spike followed by normalization. In August, Cardio Diagnostics hosted an investor conference call and continued to build out its commercial infrastructure, most notably advancing toward full in-house test processing at a high-complexity, CLIA-certified laboratory in Iowa City. That operational milestone gives the company greater end-to-end control over its testing workflow and is central to its scaling strategy.
At the same time, the company has worked to expand access to its tests, including payer coverage arrangements with provider networks such as Atlas Healthcare Physicians, and has continued publishing research and reports on rural cardiovascular care. Despite these steps, the stock's quarterly performance underscores that early-stage commercialization has yet to translate into meaningful revenue growth, keeping the share price sensitive to liquidity, sentiment, and execution headlines rather than fundamentals alone. I’m watching this closely as commercialization milestones unfold.
CDIO Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important near-term catalyst is the company's third-quarter 2026 earnings report and management commentary, expected in November 2026. Investors will focus on revenue progression, cash position, operating expenses, and any updates on test volume and reimbursement. Given the firm's modest top-line figures and ongoing net losses, clarity on the path toward commercialization and reduced cash burn will be central to the outlook.
Beyond earnings, watch for progress on payer coverage expansion, utilization of the new in-house CLIA laboratory, and any new distribution or provider partnerships. Macroeconomic factors, including access to capital for early-stage healthcare companies and general risk appetite, also matter for a micro-cap name with limited liquidity. As always, the figures and events referenced here are subject to change, and investors should consult primary filings and disclosures before drawing conclusions.
Using Tickeron AI Tools for Deeper Analysis
In my view, tools like these can help cut through the noise for names with limited liquidity. I’ve found Tickeron’s AI Trading Bots particularly useful for testing how automated strategies might approach volatile micro-caps like this one, allowing me to simulate different holding periods and risk parameters without committing capital upfront. The platform offers hundreds of AI-driven bots across thousands of tickers, and reviewing the top performers on relevant pages gives a practical sense of current algorithmic positioning. This approach has helped me frame scenarios around earnings and commercialization updates in a more structured way.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CDIO's RSI Oscillator recovers from oversold territory
The RSI Indicator for CDIO moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 50 similar instances when the indicator left oversold territory. In 46 of the 50 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 38 of 54 cases where CDIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for CDIO just turned positive on November 06, 2026. Looking at past instances where CDIO's MACD turned positive, the stock continued to rise in 20 of 38 cases over the following month. The odds of a continued upward trend are 53%.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDIO advanced for three days, in 113 of 154 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
CDIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 58 of 136 cases where CDIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 43%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CDIO as a result. In 47 of 64 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
CDIO moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CDIO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.654) is normal, around the industry mean (3.498). P/E Ratio (-0.566) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (322.581) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. CDIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology